NantHealth’s Eviti Connect Data Shows Recycling of Chemotherapy & Biologics for Advanced CRC Patients More Common Than Swit...
January 25 2020 - 9:30AM
Business Wire
NantHealth Presented These Findings at the ASCO
2020 Gastrointestinal Cancers Symposium
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare company, today announced
new real-world data on treatment patterns for patients with
advanced colorectal cancer (CRC) during a poster session at the
2020 Gastrointestinal Cancer Symposium sponsored by the American
Society of Clinical Oncology (ASCO).
The Symposium, held at the Moscone West Building in San
Francisco, CA from January 23-25, provides evidence-based teaching
methods and cutting-edge learning science to a diverse audience of
leaders in oncology education, doctors and care teams.
NantHealth’s presentation examined therapeutic preferences and
treatment patterns among advanced CRC patients using data from
NantHealth’s Eviti Connect, an evidence-based treatment
intelligence and web-based oncology decision support platform.
Detailed information from 6,325 treatment plans was analyzed to
identify treatment patterns using regorafenib and trifluridine +
tipiracil for advanced CRC patients as third-line of therapy.
National Comprehensive Cancer Network (NCCN) guidelines state that
regorafenib and trifluridine+tipiracil are both treatment options
for patients who have progressed through all available
regimens.
Across all 6,325 treatment plans submitted for this patient
population, regorafenib (n=217) or trifluridine+tipiracil (n=144)
was the submitted treatment in 361 (5.5%) of the treatment plans,
making them the 9th and 13th most frequently requested drugs
(excluding growth factors, anti-emetics, and leucovorin) in this
setting. While the total number of treatment plans for regorafenib
was higher than that for trifluridine+tipiracil, the submission of
trifluridine+tipiracil has increased over time, consistent with the
latter drug’s more recent introduction into the market.
“Our analysis shows that recycling of chemotherapy and biologics
in the late line setting is common and occurs more frequently than
switching to a drug regimen with an alternative mechanism of
action,” said William A. Flood, MD, MS, Chief Medical Officer for
Eviti, NantHealth. “As results cannot be fully explained by
clinical trial outcome differences, NCCN guidelines preferences, or
HEOR measures, we must delve deeper into why these therapeutic
patterns exist to further our mission of optimizing patient
outcomes and enabling value-based care in oncology. The uncertainty
of what constitutes the ‘best’ treatment for this patient
population provides an excellent opportunity to employ available
data to guide patient-centered decision making and value-based care
initiatives.”
Title: “Real world data on treatment patterns of advanced
CRC in 3rd line and beyond”
Authors: William A. Flood MD MS, Neil Margolis Ph.D.,
Vlad Kozlovsky, Sandeep K. Reddy MD
Abstract #56, Poster Session and Number: C – Anal
and Colorectal Cancer
Location: Moscone West Building, Level 1, West Hall
Date and Time: January 25, 2020, 6:30-7:55 AM PT and
12:15-1:45 PM PT
“Our Eviti platform enables access to near-real time data on
physician behavior which can provide unique and critical
information to pharma, payers, and provider networks to optimize
treatment strategies,” said Sandeep “Bobby” Reddy, MD, Chief
Medical Officer, NantHealth.
About NantHealth:
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payors, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting-edge data and technology
toward the goals of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in payor/provider
platforms that exchange information in near-real time (NaviNet and
Eviti), connected care solutions that deliver medical device
interoperability (DCX device connectivity platform and VCX patient
vitals software) and molecular profiling services that combine
comprehensive DNA & RNA tumor-normal profiling with
pharmacogenomics analysis (GPS Cancer®). For more information,
please visit www.nanthealth.com or follow us on Twitter, Facebook
and LinkedIn.
Forward-Looking Statements: NantHealth
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with, key
thought leaders or payers’ key decision makers in order to
establish GPS Cancer as a standard of care for patients with
cancer; our ability to grow the market for our Systems
Infrastructure, and applications; successfully enhancing our
Systems Infrastructure and applications to achieve market
acceptance and keep pace with technological developments; customer
concentration; competition; security breaches; bandwidth
limitations; our ability to continue our relationship with
NantOmics; our ability to obtain regulatory approvals; dependence
upon senior management; the need to comply with and meet applicable
laws and regulations; unexpected adverse events; clinical adoption
and market acceptance of GPS Cancer; and anticipated cost savings.
We undertake no obligation to update any forward-looking statement
in light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200125005008/en/
MEDIA CONTACT NANT Jen Hodson Jen@nant.com
562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Apr 2023 to Apr 2024